If you are wondering whether AstraZeneca's share price still offers value or is starting to look expensive, the next sections will walk through what the current market price might be implying.

Why AstraZeneca is on investors’ radar today AstraZeneca (LSE:AZN) has drawn attention after a period of solid recent share ...

AstraZeneca stock rose 230p (1.64 per cent) to 14,118 per share within an hour of the London stockmarket opening this morning ...

AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

AstraZeneca stock rose moderately Tuesday morning on better-than-expected sales and profit in the fourth quarter.

Shore Capital downgraded drugmaker AstraZeneca from 'buy' to 'hold' on Friday, stating the drugmaker's near‑term earnings ...

AstraZeneca has reported a robust rise in revenue in 2025, driven by strong demand for its cancer medicines, and struck an ...

My thesis initiates coverage of big pharma stock AstraZeneca, with an initial buy rating, agreeing with today's bullish consensus. Positive upside is driven by the diverse portfolio of solutions to ...

In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ...

By Pushkala Aripaka, Bhanvi Satija and Maggie Fick LONDON, Feb 10 (Reuters) - AstraZeneca forecast steady profit growth in ...

Pascal Soriot suggests UK-US agreement will not be enough to revive plan to expand Cambridge site ...